Adefovir dipivoxil is a novel nucleotide analogue with several promising in vitro anti -human immunodeficiency virus (HIV) characteristics. To evaluate the safety and efficacy of adefovir dipivoxil monotherapy, a randomized, double-blind, placebo-controlled study was initiated involving 72 subjects with moderately advanced HIV disease. Subjects were randomly assigned in a 2:1 ratio to receive adefovir dipivoxil or placebo as a once-daily oral dose for 6 weeks, followed by 6 weeks of open-label adefovir dipivoxil. Two dose levels were studied (125 mg and 250 mg). Adefovir dipivoxil was determined to be safe and well-tolerated when administered for 12 weeks. At week 6, changes in absolute CD4 T cell levels and HIV-1 RNA levels were significantly greater with adefovir dipivoxil than with placebo. These effects were sustained through 12 weeks of treatment. As determined by standard RNA sequencing techniques, only 1 of the 24 subjects who received adefovir dipivoxil (125 mg/day) developed any genotypic change from baseline.
Infection with human immunodeficiency virus type 1 (HIVpeutic activity of some nucleoside analogues is diminished in 1) is characterized by rapid, ongoing HIV replication and a many cellular reservoirs for HIV, including macrophages and subsequent deterioration in CD4 T cell number and activity.
nonreplicating lymphocytes [3, 6, 7] . In contrast, nucleotide Current therapeutic strategies for HIV include the use of nucleanalogues require only the final two phosphorylation steps. oside analogues, often in combination with protease inhibitors Since the enzymes responsible for these final two steps are [1] . Nucleoside analogues, such as zidovudine, inhibit reverse ubiquitous, nucleotide analogues may be more active in a transcriptase activity and block the spread of HIV to uninfected broader range of cell types [8] . cells, although they have limited effectiveness in inhibiting Adefovir was selected for clinical development because of production of virus in chronically infected cells [2 -5] . Furtherits favorable therapeutic index and in vitro activity against HIVmore, the efficacy of nucleoside analogue therapy appears to 1. Specific high-level HIV-1 resistance to adefovir is difficult to wane over time. Although the reasons for this remain unclear, establish in vitro [9] . Adefovir also has potent activity in vitro the development of specific viral resistance is one critical facagainst hepadnaviruses and a wide range of herpesviruses, intor.
cluding human herpesvirus 6 and cytomegalovirus (CMV) [10, Adefovir, 9-(2-phosphonomethoxyethyl) adenine, is a novel 11]. Adefovir and ganciclovir have comparable activity against nucleoside monophosphate, or nucleotide, analogue. It offers isolates of human CMV [11] . Finally, the intracellular active several potential advantages over other reverse transcriptase diphosphorylated metabolite of adefovir has a half-life of Ç18 inhibitors. For activation, nucleoside analogues must undergo h, thus allowing for once-daily dosing. three phosphorylation steps by intracellular kinases. Since the Early clinical trials demonstrated that adefovir has low oral expression of the nucleoside kinase responsible for the initial bioavailability [12] . To improve bioavailability, two pivalic phosphorylation is cell type -and cell cycle -specific, the theraacid moieties were attached to adefovir, resulting in a prodrug, adefovir dipivoxil, that has 40% oral bioavailability and complete conversion to adefovir. When used with other oral prodrugs, pivalic acid derivatives are generally safe and well- JID 1997; 176 (December) by the treating investigator. Subjects with grade IV events were adults. In addition, a nested pilot study was conducted to exremoved from study. For subjects with grade III events, study drug plore whether adefovir dipivoxil has anti-CMV activity in HIVwas held (125 mg dose group) or reduced 50% (250 mg dose infected adults.
group) until the adverse event returned to grade II or less.
Blood samples for T cell subsets (CD4 and CD8 T cell counts), immune complex-dissociated serum p24 antigen, and plasma
Methods
HIV-1 RNA analyses were obtained at baseline, at the end of Study design. This study was a randomized, double-blind, plaweeks 1, 3, 6, 7, and 12 of dosing, and 1 month after completion cebo-controlled study of the safety, tolerance, and anti-HIV activof dosing (week 16). HIV-1 RNA samples were stored at 070ЊC, ity of 9-[2-(bispivaloyloxymethoxy)phosphinylmethoxyethyl]adebatched, and then analyzed by a reverse transcriptase-quantitative nine (adefovir dipivoxil) administered to HIV-infected patients.
polymerase chain reaction (RT-PCR) assay (Amplicor) at the LabEligible patients were randomized in a 2:1 ratio to receive adefovir oratory Corporation of America (Research Triangle Park, NC). dipivoxil or placebo orally once a day for 6 weeks. At the end of Anti-CMV activity. At the Mt. Zion/UCSF site, men were the 6 weeks, all subjects completing the blinded phase of the study asked to enroll in a nested study examining the effect of adefovir immediately received an additional 6 weeks of adefovir dipivoxil.
dipivoxil on CMV DNA concentrations in semen samples. SamAt the end of the 12-week study period, adefovir dipivoxil was ples were collected within 24 h of the clinic visit and refrigerated discontinued, and the subjects were asked to return at week 16. until brought to the clinic. The semen samples were then immediDuring this 4-week period, subjects were asked not to take other ately analyzed by an experimental branched-chain DNA assay antiretroviral therapy.
(Chiron, Emeryville, CA), as described in detail elsewhere [15] . Two dose levels were studied: 125 mg daily and 250 mg daily.
This assay uses CMV oligonucleotide probes to hybridize CMV. The first 36 patients enrolled received 125 mg/day adefovir dipiIf specific hybridization occurs, a second hybridization step is used voxil (24 patients) or matching placebo (12 patients), while the to amplify the signal. In the final step, the amplifier is detected subsequent 36 patients received 250 mg/day adefovir dipivoxil (24 with a dioxetane substrate that generates chemiluminescence and patients) or matching placebo (12 patients). Study medications is measured by a luminometer. Semen samples were scheduled for were administered orally once a day after breakfast as one (125 collection at baseline and at the end of weeks 1, 3, 6, 7, and 12. mg dose) or two (250 mg dose) tablets containing either adefovir Genotypic analysis. Plasma HIV-1 RNA samples before and dipivoxil (125 mg/tablet) or placebo (supplied by Gilead Sciences, after therapy with adefovir dipivoxil were sequenced by use of a Foster City, CA).
technique described elsewhere [16] . Briefly, samples were thawed Patients. Male and nonpregnant female patients aged and dispensed into 1.5-mL tubes and centrifuged for 30 min at with documented HIV-1 infection were eligible. Inclusion criteria 12,500 g at 4ЊC. The supernatant was removed, and the remaining included a CD4 T cell count §200 cells/mm 3 on at least one virion pellet was resuspended in 140 mL of water. The RNA was measurement within 28 days before enrollment and a plasma HIVthen extracted and purified by using the manufacturer's instructions 1 RNA titer §10,000 Eq/mL determined by branched DNA assay for the Qiamp Viral RNA kit (Qiagen, Chatsworth, CA). Reverse within 35 days before enrollment. Patients with prior antiretroviral transcription of viral RNA to cDNA was done by adding 31 mL therapy use were allowed; however, patients were required to disof viral RNA to the kit (You Prime First Strand cDNA Synthesis continue all antiretroviral therapies for 2 weeks before randomizaKit; Pharmacia, Piscataway, NJ) and the primer RT21 (200 ng; tion and received no other antiretroviral therapies during the 12-5-CTGTATTTCTGCTATTAAGTCTTTTGATGGG-3). The reweek study period. Other eligibility criteria included a Karnofsky action mixture was incubated for 1 h at 37ЊC and then placed on performance score §70; serum creatinine £l.5 mg/dL; total biliruice. bin £l.5 mg/dL; hepatic transaminases £80 IU/L; pancreatic amyAll of the first-strand cDNA product served as the template for lase within normal limits; absolute neutrophil count ú1000/mm 3 ; nested PCR. The first PCR reaction was carried out with the primplatelets §75,000/mm 3 ; and hemoglobin §9.0 g/dL for women ers RT18 (250 ng; 5-GGAAACCAAAAATGATAGGGGGAAand §10.0 g/dL for men. Subjects with active serious infections TTGGAGG-3) and RT21 (which was added for the cDNA step), (requiring parenteral antibiotics), significant cardiac disease, and dNTPs, 2.5 U of long template PCR enzyme (Expand; Boehringer malignancies other than cutaneous Kaposi's sarcoma were exMannheim, Indianapolis), and 10 mL of buffer 1 in a final volume cluded. Subjects with hepatitis B e antigenemia or who were posiof 100 mL. Thirty cycles of PCR (94ЊC for 60 s, 55ЊC for 60 s, tive for serum antibody to hepatitis C virus were also excluded.
and 72ЊC for 120 s) were done in a thermal cycler. Ten microliters Study evaluations. Patients were evaluated weekly for 12 of the first PCR product then served as template for the second weeks. At each visit, patients were examined, and hematology and PCR reaction, which used primers RT19 (250 ng; 5-GGACATserum chemistry analyses were done. Serum carnitine levels were AAAGCTATAGGTACAG-3) and RT20 (250 ng; 5-CTGCCAtested at baseline and at the end of weeks 1, 3, 6, 7, and 12 of GTTCTAGCTCTGCTTC-3) and the same conditions as the first dosing. All laboratory tests were repeated 1 month after completion PCR reactions. of dosing (end of week 16). Symptoms, signs, and laboratory
The second-round PCR products were analyzed by agarose gel abnormalities were graded by use of a graded toxicity scale. This electrophoresis and ethidium bromide staining (1-kb product). The scale is based on the AIDS Clinical Trials Group of changes in CD4 cell counts and HIV RNA through the completion of the blinded phase of dosing (study week 6) were assessed NOTE. Each group had 24 subjects. Data are no. of patients.
by both absolute change from baseline at week 6 and the average * Events reported in ú5% of adefovir dipivoxil recipients.
change minus baseline from baseline to week 6 for all subjects † Localized pain of nonspecific etiology.
who had both baseline and week 6 samples. dosing and the 4-week follow-up period. Four patients discontinued therapy early, all for reasons considered unrelated to the study drug: 1 for noncompliance, 1 for suicide, 1 to enter an Results inpatient alcohol rehabilitation program, and 1 for a grade IV drug reaction attributed to trimethoprim-dapsone. Thirty-two Baseline characteristics. As shown in table 1, the baseline of the 36 patients enrolled at the 250 mg/day dose completed characteristics of the treatment groups were similar. The majorthe 12-week study. Four patients discontinued therapy early ity of subjects were men (94%). The mean age of the study for adverse events considered to be possibly or probably drugsubjects was 41 years. The predominant risk factor for HIV related: 2 developed nausea and vomiting, 1 developed dysuria infection was homosexual contact (92%). The mean CD4 T with a genital ulcer, and 1 developed fevers and chills. lymphocyte count at entry for the entire study group was 339 Table 2 outlines all adverse events of moderate or greater cells/mm 3 (range, 138 -1220), while the median baseline severity (grade II or greater) reported in ú5% of patients replasma HIV-1 RNA level was 4.9 logs. Three-quarters of the ceiving adefovir dipivoxil during the initial 6 weeks of blinded study population were heavily pretreated with antiretroviral therapy. The most common event was nausea, which appeared therapy (predominantly zidovudine). The median duration of to be dose-dependent. At 125 mg daily, 3 of the 24 patients who received adefovir dipivoxil developed nausea of moderate severity. None of these patients discontinued study drug. At in semen CMV levels of 0.3 log luminometer units (LU)/mL * Includes crossover patients from placebo to active drug.
at week 6 (table 5) . In contrast, the 5 patients who received 125 mg of adefovir dipivoxil daily had a 0.7 log LU/mL decrease in semen CMV (at week 6), while the 5 subjects who received were judged to be possibly drug-related. These abnormalities the 250-mg dose had a 0.3 log decline (at week 6). Considering resolved after study drug discontinuation.
the limited number of subjects in each group, detailed statistical T cell subsets. At baseline, the mean CD4 T lymphocyte analysis was not done. count was similar in all dose groups (table 1). Patients randomSerum carnitine. Administration of pivaloyloxymethyl-esteriized to placebo had a mean decline from baseline of 41 cells/ fied drugs, such as some penicillin derivatives, results in reduced mm 3 at week 6 (table 4) . In contrast, patients who received serum carnitine concentrations [13] . Therefore, we prospectively 125 mg of adefovir dipivoxil daily had a mean increase of 46 monitored serum carnitine levels during this study. In the 125-cells/mm 3 (25% -75%, 0 -72 cells/mm 3 ) at week 6 (P Å .013 mg dose group, free carnitine levels in serum were reduced 37% compared with placebo, Wilcoxon rank sum test). This increase at week 6 and 42% at week 12. In the 250-mg dose group, the persisted for the entire 12 weeks of treatment (mean absolute mean reduction was 53% at week 6 and 62% at week 12. After increase, 57 cells/mm 3 at week 12). When all time points (basediscontinuation of adefovir dipivoxil dosing, serum carnitine levline and weeks 1, 3, 6, 7, and 12) were analyzed, similar results els returned toward baseline. No patients demonstrated signs or were seen (data not shown).
symptoms of weakness, myopathy, cardiomyopathy, or encephaPatients randomized to receive 250 mg/day had a mean absolopathy suggestive of carnitine deficiency states during the 12-lute CD4 T cell increase of 15 cells/mm 3 at week 6 (P Å .21 week study. Carnitine supplements were not used. compared with placebo, Wilcoxon rank sum test). At week 12, Genotypic analysis. By standard manual DNA sequencing the mean CD4 T cell count in these patients was 27 cells/mm 3 techniques, genotypic analysis of all subjects receiving 12 above baseline.
HIV-1 RNA levels. The effect of adefovir dipivoxil on plasma HIV-1 RNA levels is presented in figure 1 . Data are weeks of continuous adefovir dipivoxil (125 mg/day) was done, ruses, herpesviruses, and hepadnaviruses. As a nucleotide anaboth at baseline and week 12. Of the 24 subjects, 19 had logue, adefovir dipivoxil appears to be active in all phases of available samples at both time points (2 subjects had no basethe cell cycle and in a broad range of cell types, including line sample available; 3 subjects had no week 12 sample).
resting nonactivated lymphocytes and macrophages [6] . FurCodons 1 -300 of the reverse transcriptase gene were sethermore, viral resistance appears to be difficult to establish in quenced. Compared with baseline, only 1 subject exhibited any vitro [9, 17] . Considering these properties, and the favorable genotypic change. This subject, who had received zidovudine pharmacokinetic profile of adefovir dipivoxil, a double-blind, in the remote past, developed an M184V mutation at week 12.
placebo-controlled, randomized study was initiated to evaluate Despite the development of this mutation, the subject had a the drug's safety and efficacy. When given over a 12-week 1.95 log decline in plasma HIV-1 RNA from baseline through period, adefovir dipivoxil appeared to be safe and had greater week 12 of dosing. Mutations selected for in vitro by adefovir, immunologic and virologic activity than did placebo. including K65R and K70E, were not seen in these subjects.
Although the number of patients in this study was too small to allow for definitive conclusions, the 125-mg dose level appeared to be better tolerated than the 250-mg dose level. Of Discussion the 36 patients who received the 125-mg dose, none required Adefovir dipivoxil is an orally available nucleotide analogue dose modifications or drug discontinuation for drug-related adwith potent in vitro activity against a wide spectrum of retroviverse events. However, at 250 mg/day, nausea, diarrhea, and asthenia occurred more frequently. Significant laboratory abnormalities were uncommon, although dose-related mild to [23] . Adefovir dipivoxil administration results in a significant drop placebo group had, as expected, no change in plasma HIV-1 RNA levels over the first 6 weeks of treatment.
in serum carnitine levels. Carnitine is an essential cofactor in fatty acid oxidation, facilitating the transfer of long-chain fatty The lack of a clear dose response in this study remains to be explained. Compared with the 125-mg dose group, the 250-acids across mitochondrial membranes. The decrease in serum levels is likely a consequence of the pivaloyloxymethyl moiety mg study group had more frequent dosing interruptions and had an increased time off study drug because of adverse events, used to enhance the bioavailability of adefovir. A recent report demonstrated that the administration of pivaloyloxymethyl-esresulting in less drug exposure and possibly reduced efficacy on surrogate markers. The role of reduced drug exposure in terified antibiotics results in an increased excretion of pivaloyl esters of carnitine and a consequent drop in serum carnitine decreasing the antiretroviral activity of the 250-mg dose in this study is supported by results of a 2-week phase I study of levels [13] . The clinical significance of reduced serum carnitine concenadefovir dipivoxil [14] . During this study, each patient received directly observed administration of adefovir dipivoxil for 14 trations is unclear. Severe congenital carnitine deficiency is associated with symptoms of myopathy, cardiomyopathy, endays. The antiretroviral effects at the end of 2 weeks were slightly, but not significantly, greater in the 250-mg dose group cephalopathy, and hypoglycemia. Acquired carnitine deficiency states may occur in patients with chronic conditions, than in the 125-mg dose group. On the basis of antiretroviral activity and tolerability, 125 mg of adefovir dipivoxil daily such as renal failure requiring dialysis, and after administration of certain drugs (e.g., pivampicillin, valproic acid). However, appears to be the optimal dose for treatment of HIV infection.
The development of viral resistance continues to limit the the importance of the secondary carnitine deficiency is unknown, nor is it clear whether carnitine supplementation beneeffectiveness of antiretroviral therapy in HIV disease. In vitro, all currently available antiretroviral nucleoside analogues select fits these patients [24] . In this short-term study, no patient developed symptoms of carnitine deficiency. In future clinical for specific and reproducible mutations in the reverse transcriptase gene. By use of similar in vitro assays with adefovir, trials of adefovir dipivoxil, patients will be provided L-carnitine supplements. high-level resistance has not been generated. Resistant HIV-1 variants have been isolated in vitro with mutations at codons In summary, adefovir dipivoxil is an orally available nucleotide analogue with convenient once a day dosing. In this 12-65 (K65R) and 70 (K70E) of reverse transcriptase, but the variants showed only 10-to 15-fold reduction in susceptibility week monotherapy study, 125 mg of adefovir dipivoxil once daily appeared to be well-tolerated and had moderate anti-HIV to adefovir, compared with the Ç100-to 1000-fold decrease in susceptibility conferred by genotypic changes selected for activity. The reduction in plasma HIV-1 RNA levels observed with adefovir dipivoxil monotherapy is similar in degree to by zidovudine or lamivudine [9, 17, 18] . In this limited 12-week study, no subject receiving continuous daily dosing of that reported with nucleoside analogue monotherapy but less dramatic than results seen with HIV-1 protease inhibitors. Pre-125 mg of adefovir dipivoxil developed K65R or K70E mutations. Only 1 subject developed any change from baseline; liminary in vitro and in vivo data suggest that high-level drug resistance to adefovir dipivoxil may not be a factor limiting this subject developed the M184V mutation, which has been reported with lamivudine therapy and, in rare cases, with didathe long-term use of this drug. Larger studies to characterize the clinical benefits of adefovir dipivoxil as therapy in HIV nosine and zalcitabine therapy. Interestingly, the emergence of M184V was not associated with the loss of virus suppression, disease are currently underway. suggesting that this mutation does not confer clinical resistance to adefovir dipivoxil. Viruses expressing the M184V mutation
